ACTU: Oral elraglusib shows strong survival benefits and synergy, with pivotal trials set to begin soon
Oral elraglusib is advancing to clinical trials, aiming to improve survival in metastatic pancreatic and other cancers, with strong efficacy and synergy data supporting its use in combination regimens. Pediatric trials and regulatory strategies are underway, with the oral pivot expected to enhance…